Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Discussion br Conflict of interest br Acknowledgements
2022-04-08

Discussion Conflict of interest Acknowledgements We thank Rosetta Barkley for expert technical assistance. We thank Robin Maser, James Calvet, Darren Wallace, and Jovanka Koo for many helpful discussions and expert technical advice. This work was supported by National Institutes of Health,
-
Synthesis of these hydrazide inhibitors is outlined in Conde
2022-04-08

Synthesis of these hydrazide inhibitors is outlined in , . Condensation of Boc-carbazate with desired aldehyde resulted in hydrazone of type which were reduced to alkylated hydrazides using NaBH and toluenesulfonic acid. The resulting alkylated hydrazides were acylated with PD173955 chlorides or
-
br Author Contributions br Acknowledgments We
2022-04-08

Author Contributions Acknowledgments We thank Hiroyuki Miyoshi, Makoto Nakanishi, Yoshikazu Johmura, Yuki Okada, Yoshinori Makino, Takashi Sutani, and Katsuhiko Shirahige for kindly providing materials and technical information, Shiho Takahashi-Kariyazono for technical advice, and all members
-
Pharmacologic approaches of inhibiting GSNOR activity have
2022-04-08

Pharmacologic approaches of inhibiting GSNOR activity have reached the point of clinical development with the recent announcement of the first cystic fibrosis patients treated with the first-in-class GSNOR inhibitor, N6022 (N30 Pharmaceuticals). Clinical development is ongoing for other indications
-
Given the involvement of dysregulated S nitrosylation in mul
2022-04-08

Given the involvement of dysregulated S-nitrosylation in multiple pathological conditions, a number of approaches to regulate S-nitrosylation therapeutically are being tried in multiple indications [18]. In the lung, GSNO releasing compounds and GSNOR inhibitors are being considered as potential the
-
cAMPS-Rp, triethylammonium salt Notably Cu labeled dimeric e
2022-04-08

Notably, 64Cu-labeled dimeric exendin-4 subunit, which was designated as 64Cu-Mal2Sar-(exendin-4)2, showed higher tumor uptake than that of the monomeric exendin-4 subunit [245]. Besides the most commonly-used GLP-1R agonists exendin-3 and -4 and their derivatives, exendin (9-39) exhibits strong bin
-
With an ever increasing incidence rate
2022-04-08

With an ever-increasing incidence rate of type 2 diabetes and obesity, it is imperative to develop new therapeutic regimes that may provide a benefit both in terms of efficacy and tolerability. The existing portfolio of drugs for the treatment of metabolic disorders, primarily type 2 diabetes and ob
-
121 4 receptor To overcome these limitations investigators h
2022-04-08

To overcome these limitations, investigators have developed novel strategies for identifying and purifying gonadotropes from transgenic mouse models. For example, FSH-producing gonadotropes have been tagged in vivo with a transgenic cell surface antigen (H-2Kk) so that they can be purified in vitro
-
After initial validation of the ability of
2022-04-08

After initial validation of the ability of Ad5-Cre virus to express Cre recombinase protein in glial cells in vitro and in vivo, we employed this virus to induce site-specific deletion of our target GlyT1 in the thalamus, through injection of the cKO GlyT1 mice. This transgenic line was constructed
-
Using expression of TcMYH fused
2022-04-08

Using expression of TcMYH fused to GFP, it was observed that MYH is present in the nucleus and in the mitochondrion of T. cruzi (Fig. 5). It is known that MYH protein from human, rat and mouse exhibits both mitochondrial and nuclear localization (Ichinoe et al., 2004, Lee et al., 2004, Nishioka et a
-
br Materials and methods br Results In this study we
2022-04-08

Materials and methods Results In this study we re-examined the kinetics of ET transport and tested the ability of various suggested substrates of OCNT1 to inhibit ET uptake. Using a native ET transporter expressed in the human HeLa cell line ET was found to be taken up with a Km of 51 μM and V
-
In conclusion we demonstrated that extrasynaptic glutamate
2022-04-08

In conclusion, we demonstrated that extrasynaptic glutamate could in situ affect the AA metabolism via brain CYPs. CYP1B1 and CYP2U1 genes in the astrocytes are the downstream genes of CREB, and the up-regulation of CYP1B1 and CYP2U1 expression by glutamate was due to the increases in phosphorylated
-
In respect of clinical development Takeda has pioneered the
2022-04-08

In respect of clinical development Takeda has pioneered the field with the GPR40 agonist TAK-875 or fasiglifam (Figure 2A), which in phase-II studies decreased HbA1c as efficiently as sulfonylurea without signs of hypoglycemia [24]. This was obtained with surprisingly little effect on systemic insul
-
The energy required to drive the
2022-04-08

The energy required to drive the functional process to actively maintain lens transparency is primarily derived from the metabolism of glucose. Since the lens is avascular and exists in an environment of low oxygen tension, glucose is primarily metabolized by Sodium Orthovanadate glycolysis (Kinoshi
-
With the exception of R none of the
2022-04-08

With the exception of R5.40310, none of the other residues would appear to be in a position to mediate direct agonist interactions in the active state GLP-1R structures. ECL2 within the GLP-1R is important for affinity and efficacy of both extended and processed GLP-1 peptides [24]. Though distal fr
15651 records 436/1044 page Previous Next First page 上5页 436437438439440 下5页 Last page